Size Exclusion Chromatography: How to Select an SEC Column and Optimize a Method

Accurate characterization of monoclonal antibody (mAb) aggregates has huge significance in the development of new therapeutic agents. The presence of mAb aggregates can affect the efficacy of the therapeutic agent and cause safety implications. In biopharmaceutical development the quantitation of aggregate is a critical quality attribute with the determination of monomer, dimer as well as higher order structure commonly achieved with size exclusion chromatography. Hence selection of SEC column and optimizing method place a crucial role.

Key Learning Points:

• Overview of column portfolios & their particle chemistries.
• Ultra High Performance SEC with sub-2 µm Particles
• Buffer Optimization for SEC
• Native SEC Mass Spectrometry (MS)

Who Should Attend:

Anyone in the biologics/Biopharmaceutical industry working on Recombinant Proteins and Academia domain.

Presenter: Mahesh Thondawada, PhD (Business Development Manager Biopharma at Phenomenex)